# OnCo record ghassan-abou-alfa (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/ghassan-abou-alfa/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "ghassan-abou-alfa" ;
  schema:name "Ghassan K. Abou-Alfa"@en ;
  schema:description "Led HIMALAYA and ClarIDHy, which gave liver cancer a dual-immunotherapy option and biliary cancer its first targeted drug."@en ;
  schema:url <https://onco.cc/people/ghassan-abou-alfa/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Abou-Alfa%20GK%5BAuthor%5D%20hepatocellular%20OR%20cholangiocarcinoma> ;
  onco:tag "hcc", "biliary", "trialist" ;
  schema:jobTitle "Attending Physician, Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center" ;
  schema:sameAs <https://orcid.org/0000-0002-1522-8054> ;
  onco:cancers <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/cholangiocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/idh/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/ctla4/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/> ;
  onco:trials <https://onco.cc/trials/himalaya/>, <https://onco.cc/trials/claridhy/> ;
  onco:journals <https://onco.cc/journals/nejm-evidence/> ;
  schema:affiliation <https://onco.cc/institutions/mskcc/> .